BioSpace News Archive

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the first minimally-invasive heart procedure using its new real-time 3D intracardiac echocardiography (ICE) catheter

A Phase 1 study on new drug candidate IDG16177 of novel oral treatment for type 2 diabetes, which is being developed by Ildong Pharmaceutical, is initiated in Germany.

Plexxikon, a member of the Daiichi Sankyo Group and a leader in structure-guided discovery and development of novel small molecule pharmaceuticals, today announced that Chao Zhang, PhD, has been promoted to chief executive officer from chief scientific officer.

Recent clinical validation of Apollo Health’s ReCODE Protocol™ — an intervention designed to reverse cognitive decline — could finally bring relief to millions who suffer from dementia.

Pharvaris announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology Annual Congress 2021, to be held virtually July 10-16, 2021.

Concert Pharmaceuticals, Inc. will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.

EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, announced the appointment of Carlos Garcia-Echeverria, Ph.D., as chief of Rx creation.

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced the U.S. Food and Drug Administration has reviewed the company’s Investigational New Drug Application and provided a notice to proceed for a U.S.-based Phase 1 clinical trial of its HDT-301 COVID-19 RNA vaccine.

Oragenics, Inc. announced that the Company’s annual meeting of shareholders, on June 30, 2021, at 9:00 a.m. was convened and adjourned, without any business being conducted, due to lack of the required quorum.

Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced that the first patient has been dosed in its Phase 1 clinical trial with PBCAR19B, an immune evading allogeneic CAR T stealth cell candidate for patients with relapsed/refractory non-Hodgkin lymphoma.